Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients.

Checkpoint inhibitors median progression free survival metastasize metastatic melanoma nivolumab

Journal

Biotechnology & genetic engineering reviews
ISSN: 2046-5556
Titre abrégé: Biotechnol Genet Eng Rev
Pays: England
ID NLM: 8510274

Informations de publication

Date de publication:
08 Jan 2023
Historique:
entrez: 9 1 2023
pubmed: 10 1 2023
medline: 10 1 2023
Statut: aheadofprint

Résumé

Metastatic melanoma has less frequency, but considered as the most dreaded cancer. The combination of nivolumab & ipilimumab is proving their mettle in treating metastatic melanoma. The patients when administered with the combination of nivolumab & ipilimumab have shown improved median progression free survival, objective response rate and overall survival rate compared with nivolumab and ipilimumab monotherapy. The combination shrinks the tumor cells by attacking different checkpoints

Identifiants

DOI: 10.1080/02648725.2022.2147683 PMID: 36617893
pubmed: 36617893
doi: 10.1080/02648725.2022.2147683
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-14

Auteurs

Mohd Wahid (M)

Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia.

Raju K Mandal (RK)

Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia.

Arshad Jawed (A)

Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia.

Ahmad Alsulimani (A)

Medical Laboratory Technology Department, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.

Anwar M Hashem (AM)

Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

Steve Harakeh (S)

King Fahd Medical Research Center, and Yousef Abdullatif Jameel Chair of Prophetic Medicine Application, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Arif Hussain (A)

School of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates.

Sharmila Fagoonee (S)

Institute of Biostructure and Bioimaging (CNR), Molecular Biotechnology Center, Turin, Italy.

Rinaldo Pellicano (R)

Unit of Gastroenterology, Molinette Hospital, Turin, Italy.

Shafiul Haque (S)

Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan, Saudi Arabia.

Classifications MeSH